Oncogenic osteomalacia is a syndrome characterized by
phosphaturia,
hypophosphatemia, reduced
vitamin D levels, and
osteomalacia. The cause is not known, but all patients have had a
tumor; usually of mesenchymal origin. Removal of the
tumor reverses the metabolic abnormalities. We report a patient with
osteomalacia, severe
hypophosphatemia, elevated
alkaline phosphatase, low
1,25-dihydroxyvitamin D3, and
phosphaturia. A
tumor was identified in the infratemporal fossa. The
tumor was removed, and all of the biochemical abnormalities resolved over the subsequent 8 months. The bone density returned to normal values. The
tumor had the appearance of a
paraganglioma and was used to establish a cell culture line called JH-55. Electron microscopy of the original
tumor and the JH-55 cells demonstrated the presence of neurosecretory granules. A bioassay using opossum kidney cells was used to evaluate
phosphate transport.
Conditioned medium from the JH-55 cells inhibited
phosphate reabsorption by the kidney tubular cells. Maximal inhibition required a 24-h incubation period and was not altered by the presence of an inhibitor of
protein synthesis (10 micrograms/mL
cycloheximide). Immunoassays revealed no detectable
PTH-related peptide or intact PTH in the JH-55 medium. The cause of this
paraneoplastic syndrome is not known, but all of the evidence is consistent with the action of a
hormone that produces
phosphaturia. This putative factor is distinct from other
hormones that cause
phosphaturia.